Promising compounds are bought, sold and partnered at all stages of the drug development process. Our experts have conducted many Due Diligence reviews and can give you the assurance you need to make a commercially sound decision.
The Right Partner
Prior to any licencing deal, it is essential you have confidence that an asset is what it appears to be. Then to assign the right value, you need to know that the data and interpretations are robust, and that forward plans are realistic.
Having been involved in Due Diligence evaluations over many years, across multiple therapy areas and asset classes, ApconiX scientists have the experience you need to help you make the right commercial decision.
ApconiX will work seamlessly with your team to provide expert technical appraisal of the nonclinical safety and DMPK data.
Our aim is for you to complete the due diligence process fully aware of all potential technical and regulatory risks in order the shape the right financial deal, or walk away.
Working as part of your Due Diligence team, we will:
- Conduct a critical review of the nonclinical safety and DMPK data
- Evaluate the authenticity of the data and interpretation of the results, highlighting potential risks and possible mitigation steps
- Critically appraise the scientific and regulatory plans and timelines
- Provide a detailed report of the investigations undertaken, risks identified and recommendations.